SPRED 1 mutations in a neurofibromatosis clinic

J Child Neurol. 2010 Oct;25(10):1203-9. doi: 10.1177/0883073809359540. Epub 2010 Feb 22.


Legius syndrome, caused by SPRED1 mutations, has phenotypic overlap with neurofibromatosis type 1 (NF1) without tumorigenic manifestations. Patients fulfilling the National Institutes of Health (NIH) diagnostic criteria for NF1 were enrolled at the University of Utah NF Clinic, and SPRED1 mutation analysis was performed to identify the frequency of Legius syndrome within an NF1 clinic population. SPRED1 sequencing was performed on 151 individuals with the clinical diagnosis of NF1, and 2 individuals (1.3%) were found to have novel SPRED1 mutations, p.R18X and p.Q194X. The phenotypes for the 2 individuals with SPRED1 mutations included altered pigmentation without tumorigenesis. A specific SPRED1 haplotype allele was identified in 27 individuals. The frequency of SPRED1 mutations in patients meeting diagnostic criteria for NF1 in a hospital-based clinic is 1% to 2%. The likelihood an individual is harboring a SPRED1 mutation increases with age if multiple, nonpigmentary NF1 findings are absent. Legius syndrome patients may benefit from altered medical surveillance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aging / genetics
  • Cafe-au-Lait Spots / diagnosis
  • Cafe-au-Lait Spots / epidemiology
  • Cafe-au-Lait Spots / genetics
  • Child
  • Child, Preschool
  • Cohort Studies
  • Comorbidity
  • Female
  • Genetic Predisposition to Disease / genetics*
  • Humans
  • Infant
  • Intracellular Signaling Peptides and Proteins / genetics*
  • Male
  • Membrane Proteins / genetics*
  • Mutation / genetics*
  • Neurofibromatosis 1 / diagnosis
  • Neurofibromatosis 1 / epidemiology
  • Neurofibromatosis 1 / genetics*
  • Young Adult


  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
  • SPRED1 protein, human

Supplementary concepts

  • Legius syndrome